Cambridge Investment Research Advisors
ARCT icon

Cambridge Investment Research Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,363
Closed -$276K – 2867
2020
Q4 		$276K Buy
+6,363
New +$431K ﹤0.01% 2212

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors's ARCT Position: Q1 2021 in Review

Cambridge Investment Research Advisors sold out of Arcturus Therapeutics (ARCT) in Q1 2021, closing a stake of 6,363 shares — an estimated $276K sold.

Cambridge Investment Research Advisors first reported a position in ARCT in Q4 2020 and held it in 1 quarter. The position peaked at $276K in Q4 2020. 162 funds tracked by Wall St. Rank hold ARCT as of Q1 2021.

  • Cambridge Investment Research Advisors reported no remaining Arcturus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,363 Arcturus Therapeutics shares in Q1 2021, an estimated $276K.
  • Cambridge Investment Research Advisors first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Arcturus Therapeutics position peaked at $276K in Q4 2020.
  • 162 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2021, filed 7 May 2021.